Andere Sprachen InnoCare Pharma Limited

Aktien

A2PVC2

KYG4783B1032

9969

Markt geschlossen - Hong Kong S.E. Andere Börsenplätze 10:08:10 26.06.2024			% 5 Tage	% 1. Jan.
4.7 ^HKD	+1.08%		+5.38%	-31.79%

21.06.	China gewährt dem Lymphom-Medikament von InnoCare den Status der vorrangigen Prüfung; Aktien steigen um 6%	MT
20.06.	InnoCare Pharma gibt die Annahme des Zulassungsantrags für Tafasitamab in Kombination mit Lenalidomid für die Behandlung des rezidivierten oder refraktären diffusen großzelligen B-Zell-Lymphoms bei erwachsenen Patienten in China bekannt	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

InnoCare Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients	21.06.
China Grants Priority Review Status for InnoCare's Lymphoma Drug; Shares Jump 6%	21.06.
InnoCare Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China	20.06.
InnoCare Pharma Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China	20.06.
Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress	14.06.
InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA	11.06.
InnoCare Pharma Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA	11.06.
InnoCare Pharma CEO Boosts Shareholding to 7.16%	31.05.
InnoCare Pharma Grants Over 1.7 Million Shares Under Incentive Scheme	31.05.
InnoCare Pharma Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis	16.05.
Innocare Pharma Posts Q1 Loss	14.05.
InnoCare Logs Loss in Q1	13.05.
InnoCare Pharma Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	13.05.
InnoCare Pharma Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib	29.03.
InnoCare Pharma Limited Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
InnoCare Pharma Limited Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China	13.03.
InnoCare to Shrink Loss in 2023	29.01.
InnoCare Pharma Limited Provides Earnings Guidance for the Year Ended 31 December 2023	29.01.
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China	24.01.
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area's Early Access Program	22.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen InnoCare Pharma Limited

Aktien

A2PVC2

KYG4783B1032

9969

Andere Sprachen

Filter